000285002 001__ 285002
000285002 005__ 20260202111826.0
000285002 0247_ $$2doi$$a10.1007/s00259-025-07600-9
000285002 0247_ $$2pmid$$apmid:41174096
000285002 0247_ $$2ISSN$$a1619-7070
000285002 0247_ $$2ISSN$$a1619-7089
000285002 037__ $$aDZNE-2026-00136
000285002 041__ $$aEnglish
000285002 082__ $$a610
000285002 1001_ $$aWeih, Fiona$$b0
000285002 245__ $$aHybrid Tau-PET/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET.
000285002 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2026
000285002 3367_ $$2DRIVER$$aarticle
000285002 3367_ $$2DataCite$$aOutput Types/Journal article
000285002 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770027338_15529
000285002 3367_ $$2BibTeX$$aARTICLE
000285002 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285002 3367_ $$00$$2EndNote$$aJournal Article
000285002 520__ $$aThe atypical Parkinsonian disorder progressive supranuclear palsy (PSP) forms a diagnostic challenge, resulting in frequent misdiagnosis and delay in treatment. Although structural MRI can detect PSP signs at more advanced stages, emerging diagnostic tools such as tau-PET and quantitative susceptibility mapping (QSM) may allow for earlier detection. This exploratory study aimed to investigate differences in QSM data of patients with PSP and healthy controls (HCs) and for the first time assess possible correlations between QSM and tau-PET data in patients with PSP to explore the relationship between tau aggregation and iron susceptibility.We retrospectively investigated differences in susceptibility values of brain structures, as assessed by QSM, between 11 HCs and 31 patients with PSP [Richardson's syndrome (PSP-RS): n = 14; other subtypes (PSP-nonRS): n = 17]. Additionally, we examined co-registered [18F]PI-2620 PET and QSM data in the 31 patients with PSP to explore the relationship between tau accumulation and susceptibility changes.Compared to HCs, patients with PSP showed higher QSM values in left nucleus caudate (p = 0.04) and bilateral dentate nucleus (p = 0.04, p = 0.01). Patients with the subtype PSP-RS showed higher QSM values than HCs in left dentate nucleus (p = 0.02). The association between the patients' QSM and tau-PET data showed a significant positive correlation.These results suggest distinct patterns of regional iron accumulation in patients with PSP and its subtypes and support an association between iron and tau pathology. The data encourage further investigation in longitudinal studies and validation in larger cohorts to examine the value of QSM as a possible diagnostic biomarker.
000285002 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000285002 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285002 650_7 $$2Other$$aMRI
000285002 650_7 $$2Other$$aPET
000285002 650_7 $$2Other$$aPSP
000285002 650_7 $$2Other$$aQSM
000285002 650_7 $$2Other$$aTau
000285002 650_7 $$2NLM Chemicals$$atau Proteins
000285002 650_2 $$2MeSH$$aHumans
000285002 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnostic imaging
000285002 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: metabolism
000285002 650_2 $$2MeSH$$aMale
000285002 650_2 $$2MeSH$$aFemale
000285002 650_2 $$2MeSH$$atau Proteins: metabolism
000285002 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000285002 650_2 $$2MeSH$$aPositron-Emission Tomography
000285002 650_2 $$2MeSH$$aAged
000285002 650_2 $$2MeSH$$aMiddle Aged
000285002 650_2 $$2MeSH$$aRetrospective Studies
000285002 650_2 $$2MeSH$$aMultimodal Imaging
000285002 7001_ $$00000-0002-2683-9432$$aRullmann, Michael$$b1
000285002 7001_ $$aHenssen, Dylan$$b2
000285002 7001_ $$aMeyer, Philipp M$$b3
000285002 7001_ $$aJochimsen, Thies$$b4
000285002 7001_ $$aSchildan, Andreas$$b5
000285002 7001_ $$aRumpf, Jost-Julian$$b6
000285002 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b7$$udzne
000285002 7001_ $$aSchroeter, Matthias L$$b8
000285002 7001_ $$aClassen, Joseph$$b9
000285002 7001_ $$aBarthel, Henryk$$b10
000285002 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b11$$udzne
000285002 7001_ $$00000-0003-0378-8334$$aTiepolt, Solveig$$b12
000285002 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07600-9$$gVol. 53, no. 3, p. 2099 - 2109$$n3$$p2099 - 2109$$tEuropean journal of nuclear medicine and molecular imaging$$v53$$x1619-7070$$y2026
000285002 8564_ $$uhttps://pub.dzne.de/record/285002/files/DZNE-2026-00136.pdf$$yRestricted
000285002 8564_ $$uhttps://pub.dzne.de/record/285002/files/DZNE-2026-00136.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285002 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285002 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b11$$kExtern
000285002 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000285002 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-07$$wger
000285002 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-07$$wger
000285002 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-07
000285002 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2025-11-07
000285002 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000285002 980__ $$ajournal
000285002 980__ $$aEDITORS
000285002 980__ $$aVDBINPRINT
000285002 980__ $$aI:(DE-2719)1110007
000285002 980__ $$aUNRESTRICTED